A New Treatment Option for Advanced Liver Cancer: Lenvatinib

Despite advances in cancer medicine, until recently we had only 1 approved treatment line for advanced liver cancer. Its biology and development differ from other cancers; when advanced, we initially choose Sorafenib, an oral targeted cancer drug. Regorafenib (Stivarga), usable when disease does not respond to Sorafenib (Nexavar), received FDA approval in April 2017 but is not yet approved for liver cancer in our country. Research highlighted at the 2017 American Cancer Congress suggested future use of Lenvatinib with the best results yet in advanced liver cancer.
Cancer appears in the liver in 2 ways. First are cancers originating in its own cells, called primary liver tumors . Second are cancers from other organs that metastasize to the liver (most commonly colorectal, lung, stomach, pancreatic and breast cancers).
The main primary liver tumor is hepatocellular cancer (hepatocellular carcinoma - HCC): of every 5 primary liver cancers, 4 are of this type. It is common worldwide and has increased in developed countries in recent years. Globally the 5th most common cancer, it is not among our country’s top 10. Approximately 1100 new liver cancers occur annually in our country.
Liver Cancer Is Examined in 3 Stages:
- Resectable localized liver cancer,
- Unresectable localized liver cancer, and
- Advanced liver cancer.
More than half of liver cancers are diagnosed at an advanced stage. This demonstrates the importance of new treatment options in a cancer with limited treatment prospects at that stage.
The REFLECT Study
Presented at ASCO 2017, REFLECT was a phase 3 trial enrolling 954 previously untreated advanced liver cancer patients with unresectable tumors. In two-thirds, cancer had spread outside the liver or involved blood vessels.
In 2015, thyroid cancer, and in 2016, kidney cancer were FDA-approved indications for Lenvatinib (trade name Lenvima), which inhibits the cell membrane’s tyrosine kinase receptor. Tyrosine kinase receptors generally support cancer cell growth, proliferation, new blood vessel formation and distant spread. Disabling these structures inactivates cancer cells and prevents new formations.
Half the patients received once-daily Lenvatinib at 8 or 12 mg, while the other half received twice-daily Sorafenib 400 mg.

Time without progression was approximately 4 months with Sorafenib, extending to 9 months with Lenvatinib. Only %9 responded completely to Sorafenib, compared with %24 receiving Lenvatinib. Median survival was approximately 14 months with Lenvatinib and approximately 12 months with Sorafenib.
What Does This Study Mean for Us?
Lenvatinib produced more effective results than Sorafenib in advanced liver cancer. However, future studies must support these findings before it becomes standard treatment. We will continue following and sharing developments.
Sources
2017 ASCO Annual Meeting. Abstract No: 4001
Was this article helpful?
Your feedback helps us improve our content.




Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.